A detailed history of D'Orazio & Associates, Inc. transactions in Novo Nordisk A S stock. As of the latest transaction made, D'Orazio & Associates, Inc. holds 8,724 shares of NVO stock, worth $1.02 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares
8,724
Previous 8,655 0.8%
Holding current value
$1.02 Million
Previous $1.11 Million 12.06%
% of portfolio
0.19%
Previous 0.18%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$122.71 - $146.91 $8,466 - $10,136
69 Added 0.8%
8,724 $1.25 Million
Q1 2024

May 08, 2024

BUY
$102.11 - $135.92 $36,963 - $49,203
362 Added 4.37%
8,655 $1.11 Million
Q4 2023

Feb 07, 2024

BUY
$87.78 - $105.45 $101,737 - $122,216
1,159 Added 16.25%
8,293 $857,000
Q3 2023

Oct 10, 2023

BUY
$90.94 - $199.54 $375,218 - $823,302
4,126 Added 137.17%
7,134 $648,000
Q2 2023

Aug 04, 2023

SELL
$155.98 - $172.65 $61,300 - $67,851
-393 Reduced 11.56%
3,008 $486,000
Q1 2023

Apr 21, 2023

SELL
$132.34 - $159.14 $12,572 - $15,118
-95 Reduced 2.72%
3,401 $541,000
Q4 2022

Jan 25, 2023

BUY
$102.55 - $135.33 $49,018 - $64,687
478 Added 15.84%
3,496 $0
Q3 2022

Oct 13, 2022

SELL
$95.28 - $116.93 $16,769 - $20,579
-176 Reduced 5.51%
3,018 $301,000
Q2 2022

Aug 15, 2022

BUY
$103.24 - $121.81 $104,272 - $123,028
1,010 Added 46.25%
3,194 $356,000
Q1 2022

May 02, 2022

BUY
$93.1 - $112.54 $203,330 - $245,787
2,184 New
2,184 $243,000
Q4 2021

Feb 07, 2022

SELL
$95.88 - $117.08 $63,568 - $77,624
-663 Closed
0 $0
Q3 2021

Nov 10, 2021

BUY
$84.42 - $106.62 $55,970 - $70,689
663 New
663 $64,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $263B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track D'Orazio & Associates, Inc. Portfolio

Follow D'Orazio & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D'Orazio & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on D'Orazio & Associates, Inc. with notifications on news.